Adamis Receives FDA Approval For 505(b)(2) Naloxone
Company Has Partnered With US WorldMeds To Launch Zimhi In Q1 2022
Executive Summary
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.